XOMA Royalty Reports Q4 Results as Portfolio Scaling Drives Long-Term Value

XOMA Royalty (NASDAQ: XOMA) has solidified its position as a premier aggregator of biotechnology royalty streams, as evidenced by its Q4 and full-year 2025 financial results. The company’s strategic transition from a traditional drug developer to a royalty-focused entity has reached a critical inflection point, with its portfolio now encompassing over 70 assets across various stages of development and commercialization. This model allows XOMA to capture the upside of high-growth therapeutics while mitigating the binary risks typically associated with clinical-stage biotech investments.

The primary driver of XOMA’s recent performance remains the stellar commercial trajectory of Vabysmo (faricimab), marketed by Roche and Genentech. As a leading treatment for wet age-related macular degeneration (nAMD) and diabetic macular edema (DME), Vabysmo has rapidly gained market share from established competitors. For XOMA, which holds a royalty interest in the underlying technology, the drug’s multi-billion-dollar annual sales provide a stable and growing foundation of non-dilutive capital. This revenue stream is complemented by the ongoing rollout of Daybue (trofinetide) by Acadia Pharmaceuticals, the first FDA-approved treatment for Rett syndrome, which has shown robust initial uptake and provides XOMA with a significant foothold in the orphan disease market.

“

Recent data indicates a 29% expansion in short interest, suggesting that some investors remain skeptical of the company's valuation or the timing of its future royalty inflows.

Beyond its commercial anchors, XOMA’s growth strategy is predicated on the aggressive acquisition of mid-to-late-stage royalty and milestone rights. In early 2026, the company continued this trend, as indicated by recent SEC filings detailing asset acquisitions and strategic partnerships. By targeting companies that need immediate capital to fund their own pipelines, XOMA is able to secure long-term royalty interests at attractive valuations. This 'capital provider' role is increasingly vital in a high-interest-rate environment where traditional equity financing for small-cap biotech firms can be prohibitively expensive or dilutive.